Cue Health Collaborates with Pfizer to Provide People who Test Positive for COVID-19 with Actionable Health Information to Better Inform their Treatment Journey
Cue Health (Nasdaq: HLTH) has announced a collaboration with Pfizer to enhance COVID-19 awareness among high-risk individuals. Utilizing the Cue Care platform, the partnership will provide educational resources accessible via the Cue Health App. This initiative aims to inform users about risks associated with severe COVID-19 and the importance of timely healthcare access.
With a focus on connected health solutions, Cue aims to improve patient care, especially for those aged 50 and older. Additionally, Cue is expanding educational resources for other health conditions in the future, strengthening its position in diagnostic innovations.
- Collaboration with Pfizer enhances awareness of COVID-19 risks among high-risk individuals.
- Cue Care platform integrates educational resources, supporting informed health decisions.
- Cue's COVID-19 test is FDA-authorized and the first molecular at-home test, ensuring accessibility.
- None.
New educational resources will make it easier for people at high risk of progression to severe COVID-19 to protect their health through accessible and timely health information
“The recent guidance from the
This COVID-19 collaboration with Pfizer builds on recent initiatives launched by Cue to rapidly connect at-risk individuals with providers for care and, where appropriate, treatment.
“Connected health solutions like the Cue platform offer potential for faster and more convenient access to care. Our collaboration provides an opportunity to improve the test-to-treatment experience for patients and communities at high risk, which includes people 50 years of age and older,” said
While these educational resources are specific to COVID-19 today, the Cue platform is designed to support a wide range of diagnostic test-to-treatment areas, and the company plans to make educational resources about treatment and recovery available for other respiratory viruses and sexual health conditions in the future.
Last month, Cue announced a partnership with
Cue’s COVID-19 test was the first molecular diagnostic test available to consumers without a prescription and is the most accurate at-home COVID-19 test*, delivering results in 20 minutes to connected mobile devices. It detects all known COVID-19 variants of concern in people with or without symptoms. Cue is used in homes, in point-of-care settings, and by world-class organizations across the country, including
An independent study by
*Accuracy claim based on comparison of clinical study results submitted to the
About
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements”. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those related to the expected future diagnostic test menu and the factors discussed in the “Risk Factors” section of Cue’s Annual Report on Form 10-K for the year ended
Cue’s COVID-19 tests have not been FDA cleared or approved; but have been authorized by FDA and under an Emergency Use Authorization (EUA). These products have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005305/en/
MEDIA INQUIRIES
press@cuehealth.com
Source:
FAQ
What is the collaboration between Cue Health and Pfizer about?
What is the purpose of Cue Care?
How does Cue Health's COVID-19 test work?
What demographic does Cue Health focus on in its new initiative?